Studybox Research CLIA Waiver Studies

Syphilis Rapid Test

Accuracy in the hands of untrained intended-use operators at waived sites.

Studybox

CLIA Waiver Studies

Syphilis incidence in the United States rose sharply over the past decade, including congenital syphilis, and same-visit treponemal testing has an obvious role. The clinical study is a serology comparison with a complication: treponemal antibodies persist for life in most people after treatment, so a reactive result cannot distinguish active from past infection. Study subjects must be characterized by stage and treatment history, and the labeling will describe the test as an aid to diagnosis requiring confirmatory and nontreponemal follow-up.

Sensitivity in primary syphilis is lower for all treponemal tests because antibodies are still developing, and this stage is where a rapid test has the most clinical value and the fewest study subjects. Enrollment typically relies on sexual health clinics and emergency departments with high syphilis volume, supplemented with characterized banked sera for staging strata that are hard to enroll prospectively.

Analyte: Treponema pallidum antibodies (treponemal), with some devices adding a nontreponemal component
Therapeutic area: STD/STI Detection
Specimens: Capillary Fingerstick Blood, Venous Whole Blood, Serum and Plasma
Intended-use settings: urgent care, physician office, pharmacy, emergency department
Operators: Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.
Comparator: Typically laboratory treponemal serology (a treponemal immunoassay and/or T. pallidum particle agglutination) with nontreponemal testing (RPR or VDRL with titer) and clinical staging; subjects are classified by a composite of serology and clinical history.

CLIA Waiver Studies specifics

What Changes for This Assay on This Pathway.

Waived operators collect fingerstick blood and apply a defined volume; flex studies typically stress volume, buffer drop count, read window and reading of faint lines, which matter because weakly reactive treponemal results are common in treated and late latent disease.
Waived sites with syphilis positives are typically sexual health clinics, emergency departments and outreach programs; the operator population at these sites must be documented as untrained in laboratory methods.
A positive result at a waived site typically triggers laboratory confirmation and treatment; the protocol should set out how site clinicians handle investigational results.

Endpoints the study must support

Sensitivity by disease stage (primary, secondary, early latent, late latent, previously treated) against the laboratory treponemal reference, with 95% confidence intervals
Specificity in a low-prevalence population without history of syphilis
Agreement across claimed specimen types (fingerstick, venous whole blood, serum, plasma)
Invalid rate and inter-operator agreement in waived settings

Enrollment realities

Driven by prospectively enrolled primary and secondary syphilis cases, which are uncommon even at high-volume clinics; banked staged sera are typically needed. Specificity enrollment at low-prevalence waived sites accrues quickly.

How Studybox runs it

Pre-Qualified Sites, Embedded Coordinators.

Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run clia waiver studies →

Same assay, other pathways

Relevant FDA guidance

FAQ

Syphilis Rapid Test Study Questions.

01 Who operates the syphilis rapid test in a clia waiver studies study?

Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.

02 What is the comparator for a syphilis rapid test study?

Typically laboratory treponemal serology (a treponemal immunoassay and/or T. pallidum particle agglutination) with nontreponemal testing (RPR or VDRL with titer) and clinical staging; subjects are classified by a composite of serology and clinical history.

03 What drives enrollment for a syphilis rapid test study?

Let's talk IVD research

Planning a syphilis rapid test study?

Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the clia waiver studies pathway.